Deletions involving chromosome 1p are frequent events in multiple myeloma (MM). As karyotyping and single nucleotide polymorphism-based mapping analysis identify a minimal common deletion region involving the 1p21 locus, we investigated the prevalence and prognostic significance of del(1p21) in 203 MM patients undergoing high-dose therapy and autologous SCT. 1p21 status was also evaluated in 16 patients with monoclonal gammopathy of undetermined significance (MGUS) and 41 patients with plasma cell leukemia (PCL). FISH combined with cytoplasmic light chain detection (cIg-FISH) detected hemizygous 1p21 deletions in 18% of the MM, 34% of PCL but none of the MGUS cases. The presence of 1p21 deletions was correlated with 1q21(CKS1B) amplification (P ¼ 0.01), and del17p(TP53) (P ¼ 0.05) but not with del(13q), t(11;14) or t(4;14). Patients with 1p21 deletions had significantly shorter progression-free survival (PFS; median 14.2 vs 25.4 months, Po0.001) and overall survival (OS; median 39.4 vs 82.3 months, P ¼ 0.001) than those without such deletions. In multivariate analysis, del(1p21) was an independent risk factor for PFS (P ¼ 0.003) and OS (P ¼ 0.013) after adjusting for del(13q), del(p53), t(4;14) and 1q21 amplifications. Our results indicate that del(1p21) is an independent poor prognostic factor associated with disease progression in MM. 
Introduction
Chromosome 1 abnormalities are among the most common cytogenetic findings in multiple myeloma (MM), constituting the structural aberrations in up to 40% of abnormal karyotypes. 1 They are associated with adverse outcome. 2 The short arm of chromosome 1 is preferentially involved in deletions and the long arm in gains. 3, 4 Recently, Marzin et al. 5 reported that 27% of 36 MM cases had 1p deletions identified by karyotype analysis, and the smallest common deletion region was 1p12-1p21. Using single nucleotide polymorphism-based mapping, Walker et al. 4 found that 7 (23%) of 30 MM cases had 1p deletions, confirming a minimal common deletion region between band 1p12 and 1p21.1. In a pilot study, we evaluated the clinical relevance of 1p21 deletions by cytoplasmic Ig interphase FISH (cIg-FISH) in a cohort of 87 MM patients, and found that 1p21 deletion confers a poor clinical outcome. 6 To further explore its prognostic significance and potential implication in the genetic risk stratification of MM, we expanded our previous observation to a larger MM cohort and examined 1p21 deletions in the context of myeloma-associated genetic risk factors including t (4;14) , del(13q), del(17p) and 1q21 (CKS1B) amplifications. In addition, we compared 1p21 status in different stages of plasma cell dyscrasia.
Materials and methods

Patients
A total of 230 MM cases accessioned and diagnosed by Durie-Salmon criteria between 1999 and 2006 were included in this study. The clinical and laboratory features were obtained at diagnosis ( Table 1 ). The median age of the 118 men and 85 women was 55 years (range, 31-73 years) at diagnosis. Of all the patients, 109 had IgG paraprotein, 45 IgA, 5 IgD, 40 light chain disease and 4 were nonsecretory. All patients were treated with 4-5 cycles of VCR, adriamycin and dexamethasone as induction and one course of melphalan 200 mg/m 2 followed by autologous SCT. The median post transplant follow-up was 36 months.
Fluorescence in situ hybridization
On institutional ethics board approval, BM aspirates were obtained from patients with active MM before any treatment. Mononuclear cells enriched by Ficoll-gradient centrifugation and cytospin slides were made and stored at À70 1C. Cytoplasmic Ig light chain immunofluorescence with simultaneous FISH analysis (cIg-FISH) was performed on fixed mononuclear BM cells on cytospin slides as previously described. 7 To investigate the 1p21 status, we identified a bacterial artificial chromosome (BAC) clone RP11-776K10 (190 kb). This clone was labeled with SpectrumOrange-dUTP using a nick translation kit (Vysis, Downers Grove, IL, USA) and used as a FISH probe. This probe has been tested extensively on mononuclear cells from normal peripheral blood and BM donors. It does not cross-hybridize with any other chromosomal region. The background cutoff for this probe is set at 10%. To ensure high hybridization efficiency, we combined a Spectrum Orange-labeled 1p21 BAC probe with a SpectrumGreenlabeled chromosome 1 classical satellite (1qh) probe. The cIg-FISH methods with appropriate probes for evaluating deletions of 13q and TP53, t(11;14), t(4;14) and CKS1B amplification were described previously. 7, 8 Statistical analysis Statistical evaluation was conducted using the Fisher's exact test, w 2 -test and nonparametric Wilcoxon test. Progression-free survival (PFS) and overall survival (OS) were calculated from the transplantation date by the Kaplan-Meier method. Differences between survival curves were analyzed by the log-rank test. Multivariate analysis 
Correlation of 1p21 deletions and clinical outcome
The median OS for this cohort was 76.5 months (95% confidence interval (CI): 62.3-86.9) and the median PFS was 22 months (95% CI: 19.4-25.0). The median interval between diagnosis and SCT was similar for patients with and without 1p21 deletions (8.5 vs 9.7 months, respectively). Patients with 1p21 deletions had a significantly shorter PFS (median, 14.2 months) than patients without 1p21 deletions (median, 25.4 months, Po0.0001; Figure 1a ). OS was also significantly shorter (median, 39.4 months) for patients with a 1p21 deletion than for patients without a deletion (median, 82.3; P ¼ 0.001; Figure 1b) . A univariate genetic risk factor analysis confirmed that p53 deletion (P ¼ 0.04 for PFS, Po0.001 for OS), 13q deletion (Po0.01 for PFS, P ¼ 0.05 for OS) and t(4;14) (P ¼ 0.05 for PFS, P ¼ 0.01 for OS) were significant. CKS1B amplification was marginal significant for PFS (P ¼ 0.06) but not OS (P ¼ 0.21). The survival differences among patients with 1p21 deletion, CKS1B amplification, t(4;14), TP53 and 13q deletion were demonstrated in Figure 1c . On multivariate analysis including the above-mentioned genetic risk factors, only 1p21 deletion and 17p deletion were significant for either PFS or OS ( Table 2) .
Detection of chromosome 1q21 deletion in different stages of plasma cell dyscrasias
To assess whether 1p21 deletion is associated with disease progression, we further evaluated 1p21 status in 16 patients with monoclonal gammopathy of undetermined significance (MGUS), 31 MM at relapse and 41 patients with plasma cell leukemia (PCL). In contrast to newly diagnosed MM, 1p21 deletion was present in 9 of 31 relapsed MM (31%) and 11 of 41 PCL (33%) but in none of the MGUS patients. 
Discussion
MM remains an incurable disease with highly heterogeneous clinical courses that cannot be accounted for by traditional laboratory parameters. It is evident that genetic aberrations have become a major prognostic factor for MM patients treated with conventional chemotherapy or autologous SCT. 7, 9 With a larger sample size and longer follow-up, here, we confirm that 1p21 deletions are associated with a poor prognosis in MM. Importantly, after adjusting for myeloma-associated genetic risk factors including deletions in 13q and 17p, t(4;14) and CKS1B amplification, 1p21 deletion remains an independent marker predicting shorter PFS and shorter OS in MM. Furthermore, the prevalence of 1p21 deletions are increased from MM at diagnosis to more advanced stages of the disease such as relapsed MM and PCL, suggesting that 1p21 deletion is associated with disease progression in MM. Thus, deletion of 1p21 is an important prognostic factor for the genetic risk stratification of MM. We recommend to include del(1p21) as a part of the routine work up for MM patients undergoing autologous SCT.
The prevalence of 1p21 deletion was 18% in this cohort of MM. In contrast to karyotyping analysis, 2,5,10,11 our study used cIg-FISH to detect specific chromosomal abnormalities within 1p. We found that MM patients with 1p21 deletions had characteristic clinical and biologic features. For the first time, we found that two distinct genomic aberrations on chromosome 1 (1p21 deletion and 1q21 amplification) were strongly correlated, which was not demonstrated in our previous report probably due to limited sample size. Chromosome 1q21 amplification has shown to be associated with poor clinical outcome in MM. [12] [13] [14] The correlation between 1p21 deletions and 17p deletion or t(4;14), two adverse risk factors in MM, 9 was confirmed in this study. In addition, 1p21 deletion is highly associated with higher CRP levels but not with other recognized markers of disease burden such as b 2 -microglobulin. This difference may reflect higher levels of IL-6 characterizing the differences in microenvironment dependence in MM.
Little is known about genetic events that promote the transformation from MGUS to MM. The common MM-associated genetic changes such as 13q deletions and IgH translocations are also found in MGUS. 15, 16 We and others have shown that genetic abnormalities such as Ras mutations 17 and 1q21 amplifications 8, 12 are detected in MM but rarely in MGUS; here, we also found that 1p21 deletion is not detectable in MGUS, suggesting this genomic aberration may be a secondary event associated with disease progression. Along with other genetic factors such as RAS mutations or 1q21 gains, 1p21 deletion may play a role in the transformation from MGUS to MM. Studies with sequential patients samples at different stages of the disease as well as functional analysis are required to confirm this observation.
The detection of 1p21 deletion as a poor prognostic factor in our cohort of MM is consistent with the karyotype analysis by other groups, 2,10,11 who found that the 1p deletions appeared to be associated with a poor clinical outcome in MM patients. Using gene expression profiling, Shaughnessy et al. 18 recently showed that 50% of the underexpressed genes in the high-risk MM group were derived from 1p, suggesting loss of certain tumor suppressor gene(s) within 1p region may contribute to the aggressiveness of MM. In an attempt to identify candidate tumor suppressor gene(s) in the minimum common deletion region on 1p, we searched the genome database and identified a BAC clone FISH Probe for 1p21 deletion analysis, this BAC clone mainly contains a gene-cyclindependent kinase phosphatase Cdc14A.
19 Cdc14A has been shown to play a role in regulating mitotic exit and the centrosome duplication cycle. 20 Recently, Paulsen et al.
21
demonstrated that Cdc14A is differentially expressed in human cancer cells and that Cdc14A can interact with both p53 and the Cdk1/cyclin B complex, implicating that dysregulation of Cdc14A expression may contribute to carcinogenesis. Our study identified that 1p21 deletions containing Cdc14A is an independent risk factor for MM, suggesting that Cdc14A dysregulation might play an important role in the development of MM. Further studies are required to understand the molecular pathogenesis of Cdc14A in MM.
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